<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259129</url>
  </required_header>
  <id_info>
    <org_study_id>100561</org_study_id>
    <nct_id>NCT00259129</nct_id>
  </id_info>
  <brief_title>Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients</brief_title>
  <official_title>Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized Phase I study of sorafenib 400 mg bid (2 x 200 mg
      tablets) in cancer patients. The primary objective of the study is to evaluate the effect of
      sorafenib on cardiovascular safety parameters. The secondary objectives are to evaluate the
      safety, pharmacokinetics, and anti-tumor activity of sorafenib in cancer patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of sorafenib on cardiovascular safety parameters</measure>
    <time_frame>up to 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>after 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>after 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Collection</measure>
    <time_frame>after 11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with refractory solid cancer for which curative or palliative measures have
             failed or patients for whom standard treatment is considered ineffective or
             intolerable

          -  Histological or cytological documentation of cancer is required

          -  Patients with at least one evaluable lesion. Lesions must be evaluated by Computed
             Tomography (CT) scan or Magnetic Resonance Imaging (MRI)

          -  Life expectancy of at least 12 weeks

          -  Left ventricular ejection fraction (LVEF) &gt;=45 % as assessed at the Baseline Multiple
             Gated Acquisition (MUGA) scan

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to dosing:

               -  Hemoglobin &gt; 9.0 g/dL

               -  Absolute neutrophil count (ANC) &gt; 1,500/mm3

               -  Platelet count &gt;=100,000/dL

               -  Total bilirubin &lt;=1.5 times the upper limit of normal

               -  Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) &lt;=2.5 x upper
                  limit of normal, except if there is metastatic disease to the liver, in which
                  case &lt;=5 x upper limit of normal is acceptable

               -  Prothrombin Time-International Normalized Ratio/Partial Thromboplastin Time
                  (PT-INR/PTT) &lt; 1.5 x upper limit of normal. Patients who are being
                  therapeutically anticoagulated with an agent such as Coumadin or heparin will be
                  allowed to participate provided that no prior evidence of underlying abnormality
                  in these parameters exists. For patients on anticoagulation therapy, at least
                  weekly evaluations will be performed until International Normalized Ratio (INR)
                  is stable as defined by the local standard of care

          -  Serum creatinine &lt;=1.5 x upper limit of normal

        Exclusion Criteria:

          -  Colorectal cancer whether refractory or not

          -  Supine systolic blood pressure greater than 170 mmHg or diastolic blood pressure
             greater than 100 mmHg (mean of duplicate readings) at Screening with or without
             antihypertensives

          -  Symptomatic metastatic brain or meningeal tumors

          -  Pregnant or breast-feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <results_reference>
    <citation>Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR. A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol. 2011 Apr;67(4):751-64. doi: 10.1007/s00280-010-1372-3. Epub 2010 Jun 3.</citation>
    <PMID>20521052</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

